The maintained guidance and solid ORLADEYO growth (+21% ex-Europe) are reassuring, but the stock is unlikely to move sharply on in-line results. The key catalyst to watch is the completion of navenibart Phase 3 enrollment by end of June 2026, which would de-risk the pipeline. The $70M upfront licensing deal provides a near-term cash buffer. Traders should monitor for any enrollment updates or guidance changes on the Q2 2026 earnings call.
Price Chart
Executive Summary
BioCryst reported Q1 2026 ORLADEYO revenue of $148.3M (+11% y-o-y; +21% on a comparable ex-Europe basis), in line with the maintained FY2026 guidance of $625-645M. The GAAP net loss of $721.8M was driven by a $697.8M non-cash charge from the Astria acquisition, but non-GAAP operating profit was $54.2M. The company also announced a $70M upfront licensing deal for European navenibart rights, with up to $275M in milestones. Guidance was maintained, and the navenibart Phase 3 enrollment is on track to complete by June 2026.
Key Financial Metrics
Key Facts
- Q1 2026 ORLADEYO net revenue $148.3M, +11% reported y-o-y, +21% on a comparable basis excluding European revenue
- GAAP net loss of $721.8M driven by $697.8M non-cash acquired IPR&D charge from Astria acquisition
- Non-GAAP operating profit of $54.2M in Q1 2026
- Full-year 2026 ORLADEYO revenue guidance maintained at $625M-$645M; total revenue guidance maintained at $635M-$660M
- Licensing agreement with Neopharmed Gentili for European navenibart rights: $70M upfront, up to $275M milestones, plus 18%-30% tiered royalties
- Navenibart Phase 3 ALPHA-ORBIT enrollment on track to complete by end of June 2026; regulatory filing targeted by end of 2027
- Cash, equivalents, restricted cash and investments at March 31, 2026: $260.8M; pro-forma including post-quarter-end $70M license proceeds: $330.8M
- Company ended development of avoralstat (DME program) in Q1 2026
- Appointed Sandeep M. Menon as Chief Research and Development Officer in April 2026
Financial Impact
Q1 ORLADEYO revenue of $148.3M was in line with the maintained $625-645M annual guidance run-rate. The $70M upfront from the navenibart licensing deal strengthens the balance sheet.
Risk Factors
- Navenibart is still in Phase 3 and unapproved; regulatory or clinical setbacks could impair the $697.8M IPR&D asset
- GAAP net loss of $721.8M and accumulated deficit of $2.23B highlight ongoing cash burn despite non-GAAP profitability
- Secured term loan of $395.2M and royalty financing obligation of $447.5M represent significant leverage
- Competition in HAE from injectable therapies (Takhzyro, Haegarda) could pressure ORLADEYO growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003052 |
| Document: f8k_050626.htm | 0001171843-26-003052 |
| Document: 0001171843-26-003052-index-headers.html | 0001171843-26-003052 |
| Document: 0001171843-26-003052-index.html | 0001171843-26-003052 |
| Document: 0001171843-26-003052.txt | 0001171843-26-003052 |
| 8-K Data (Synthetic) | 0001171843-26-003052 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $9.07 $10.17 | ▲ +12.13% | ▲ +12.73% | $8.14 (−10.25%) |
Jun 29, 2026 13w ago | 8-K | $9.55 $9.34 | ▼ −2.20% | ▼ −1.92% | $8.14 (−14.76%) |
Jun 12, 2026 15w ago | 8-K | $9.06 $9.91 | ▲ +9.38% | ▲ +10.13% | $8.14 (−10.15%) |
Jun 12, 2026 16w ago | Press Release | $8.70 $10.45 | ▲ +20.11% | ▲ +18.34% | $8.14 (−6.44%) |
May 19, 2026 19w ago | Insider Cluster | $8.74 $8.99 | ▲ +2.86% | ▲ +2.12% | $8.14 (−6.86%) |
May 13, 2026 20w ago | 144 | $9.60 $8.50 | ▼ −11.46% | ▼ −10.85% | $8.14 (−15.21%) |
May 6, 2026 21w ago | 8-K | $8.83 $8.25 | ▼ −6.57% | ▼ −9.35% | $8.14 (−7.81%) |
May 4, 2026 21w ago | 8-K | $9.20 $8.57 | ▼ −6.85% | ▼ −12.49% | $8.14 (−11.52%) |
Apr 23, 2026 23w ago | DEFA14A | $8.94 $8.37 | ▼ −6.38% | ▼ −10.40% | $8.14 (−8.95%) |
Apr 15, 2026 24w ago | Press Release | $9.44 $8.80 | ▼ −6.78% | ▼ −12.82% | $8.14 (−13.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access